This study focused on some of the sickest pulmonary arterial hypertension patients – those with advanced disease who were already on the best available treatments but still faced a high risk of dying within the next year. For these patients, doctors have traditionally had limited options.
Researchers enrolled 172 high-risk patients who were already receiving maximum doses of standard pulmonary arterial hypertension medications. Half received sotatercept injections every three weeks, while the other half received placebo injections. The results were so striking that the trial was stopped early – it would have been unethical to continue giving placebo when sotatercept showed such clear benefits.
Only 17.4% of patients receiving sotatercept experienced a major negative event (death, lung transplant, or hospitalization), compared to 54.7% of those on placebo. The breakdown was particularly impressive: hospitalizations for worsening pulmonary arterial hypertension occurred in just 9.3% of sotatercept patients versus 50% of placebo patients. Deaths were also significantly lower (8.1% vs 15.1%), as were lung transplants (1.2% vs 7.0%). The side effects – mainly nosebleeds and small red skin spots – seem manageable compared to the dramatic reduction in life-threatening events.
This study represents a significant advance in pulmonary arterial hypertension treatment, particularly for those with the most severe disease. It suggests that even when patients are on optimal therapy, innovative treatments like sotatercept can still make a meaningful difference in preventing the worst outcomes.
Read abstract at this link, full access is subscriber only
Citation
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM; ZENITH Trial Investigators. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025 May 29;392(20):1987-2000. doi: 10.1056/NEJMoa2415160. Epub 2025 Mar 31. PMID: 40167274.